First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era

First-Line Treatment of Older Patients with CLL: A New Approach in the Chemo-Free Era

Bruton tyrosine kinase inhibitors (BTKi) and the BCL2 inhibitor venetoclax, with or without the anti-CD20 monoclonal antibody Obinutuzumab, represent the preferred options for the first-line therapy of CLL because they are more effective and may improve quality of life. However, patient inclusion cr...

Full description

Bibliographic Details
Main Authors: Antonio Urso, Francesco Cavazzini, Maria Pia Ballardini, Silvia Gambara, Sara Consolo, Gian Matteo Rigolin, Antonio Cuneo
Format: Article
Language:English
Published: MDPI AG 2023-07-01
Series:Cancers
Subjects:
chronic lymphocytic leukemia
older patient
Bruton tyrosine kinase
BCL2
cost-effectiveness
Online Access:https://www.mdpi.com/2072-6694/15/15/3859

Internet

https://www.mdpi.com/2072-6694/15/15/3859

Similar Items